Journal: Cell Communication and Signaling : CCS

Article Title: Targeting cancer-derived extracellular vesicles by combining CD147 inhibition with tissue factor pathway inhibitor for the management of urothelial cancer cells

doi: 10.1186/s12964-024-01508-x

Figure Lengend Snippet: Impact of the combined inhibitors treatment on extracellular vesicle (EV)-induced migration potential. J82 human bladder urothelial carcinoma cells were exposed to 150 µg/ml protein from J82 cell-derived EVs and treated with either 5 µM CD147 inhibitor AC-73 alone ( A ) or a combination of 2.5 µM AC-73 and tissue factor pathway inhibitor (TFPI, 300 ng/ml, B ) for 16 h. Relative migration was quantified via a Transwell assay utilizing 6–8 images of cells that traversed the microporous membrane per experiment

Article Snippet: J82 cells were exposed to their own isolated and characterized microvesicle-like EVs, which were pre-incubated with or without the CD147 inhibitor AC-73 (MedChemExpress LLC, NJ), human recombinant TFPI together with factor VII (Sigma-Aldrich, MO), or human recombinant CD147 protein (rCD147, Sino Biological Europe, Germany) for the specified duration.

Techniques: Migration, Derivative Assay, Transwell Assay, Membrane

Journal: Cell Communication and Signaling : CCS

Article Title: Targeting cancer-derived extracellular vesicles by combining CD147 inhibition with tissue factor pathway inhibitor for the management of urothelial cancer cells

doi: 10.1186/s12964-024-01508-x

Figure Lengend Snippet: Impact of treatment with the combined inhibitors on extracellular vesicle (EV)-induced matrix metalloproteinases (MMPs) release. J82 human bladder urothelial carcinoma cells were treated with J82 cell-derived EVs or with a pool of isolated EVs from urine samples collected from patients with muscle-invasive bladder cancer ( A ), along with either 2.5 µM or 5 µM of the CD147 inhibitor AC-73, in the absence or presence of tissue factor pathway inhibitor (TFPI, 300 ng/ml, B ) for 24 h. Recombinant CD147 (rCD147) was used as a positive control to induce MMP activity. The induction of MMPs was measured using colorimetric enzymatic methods

Article Snippet: J82 cells were exposed to their own isolated and characterized microvesicle-like EVs, which were pre-incubated with or without the CD147 inhibitor AC-73 (MedChemExpress LLC, NJ), human recombinant TFPI together with factor VII (Sigma-Aldrich, MO), or human recombinant CD147 protein (rCD147, Sino Biological Europe, Germany) for the specified duration.

Techniques: Derivative Assay, Isolation, Recombinant, Positive Control, Activity Assay

Journal: Cell Communication and Signaling : CCS

Article Title: Targeting cancer-derived extracellular vesicles by combining CD147 inhibition with tissue factor pathway inhibitor for the management of urothelial cancer cells

doi: 10.1186/s12964-024-01508-x

Figure Lengend Snippet: Impact of treatment with the combined inhibitors on extracellular vesicle (EV)-induced invasion potential. J82 human bladder urothelial carcinoma cells were exposed to 150 µg/ml protein from J82 cell-derived EVs or with a pool of isolated EVs from urine samples collected from patients with muscle-invasive bladder cancer, and treated with either 5 µM of the CD147 inhibitor AC-73 alone ( A ) or a combination of 2.5 µM AC-73 and tissue factor pathway inhibitor (TFPI, 300 ng/ml, B ) for 24 h. Invasion potency was measured via a Transwell assay utilizing 6–8 images of cells that traversed the microporous membrane per experiment

Article Snippet: J82 cells were exposed to their own isolated and characterized microvesicle-like EVs, which were pre-incubated with or without the CD147 inhibitor AC-73 (MedChemExpress LLC, NJ), human recombinant TFPI together with factor VII (Sigma-Aldrich, MO), or human recombinant CD147 protein (rCD147, Sino Biological Europe, Germany) for the specified duration.

Techniques: Derivative Assay, Isolation, Transwell Assay, Membrane

Journal: Cell Communication and Signaling : CCS

Article Title: Targeting cancer-derived extracellular vesicles by combining CD147 inhibition with tissue factor pathway inhibitor for the management of urothelial cancer cells

doi: 10.1186/s12964-024-01508-x

Figure Lengend Snippet: Impact of treatment with the combined inhibitors on the extracellular vesicle (EV) binding capability. J82 human bladder urothelial carcinoma cells were exposed in suspension to carboxyfluorescein succinimidyl ester fluorescent dye (CFSE)-labeled J82 cell-derived EVs and treated with either 5 µM CD147 inhibitor AC-73 alone or a combination of 2.5 µM AC-73 and tissue factor pathway inhibitor (TFPI, 300 ng/ml). The cells were analyzed for green fluorescence in the FITC channel using flow cytometry

Article Snippet: J82 cells were exposed to their own isolated and characterized microvesicle-like EVs, which were pre-incubated with or without the CD147 inhibitor AC-73 (MedChemExpress LLC, NJ), human recombinant TFPI together with factor VII (Sigma-Aldrich, MO), or human recombinant CD147 protein (rCD147, Sino Biological Europe, Germany) for the specified duration.

Techniques: Binding Assay, Suspension, Labeling, Derivative Assay, Fluorescence, Flow Cytometry